OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes

ClinicalTrials.gov ID

NCT06476119

Lead Sponsor

The Netherlands Cancer InstituteOTHER

Overall Status

Recruiting

Study Type

Observational

Enrollment

490Estimated

Last Update Posted

Apr 23, 2025Actual

Start Date

Apr 15, 2025Actual

Primary Completion Date

Sep 15, 2032Estimated

Completion Date

Sep 15, 2034Estimated

Official Title

OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes

Brief Summary

The aim of this study is to investigate whether subjects with breast cancer that have certain favorable features, after performing the surgery and radiation, the chemotherapy can be safely omitted in the treatment. In addition, the investigation looks at whether the omission of chemotherapy ensures a better quality of life. Participants decide, in consultation with their treating physician, whether they choose to be treated with adjuvant chemotherapy or not.

• Breast Cancer Stage I
• Triple Negative Breast Cancer (TNBC)

• Adjuvant chemotherapy
• No adjuvant chemotherapy

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Female or male patients;

• >=18 years;

• Written informed consent;

• TNBC (defined as: invasive carcinoma; ER/PR expression 0-9%; Human Epidermal Growth Factor Receptor 2 [HER2] negative [0, 1+ or 2+ on immunohistochemistry, without HER2 amplification on in-situ hybridization]) on the diagnostic biopsy and the surgical specimen;

• Pathological stage I TNBC (according to the TNM staging 8th edition):

  • pT1a/b/c (≤2 cm), confirmed by an invasive component of ≤2 cm on the surgical specimen (microinvasive disease [pT1mi, ≤1 mm) is not allowed);
  • pN0, confirmed by absence of malignant cells in the sentinel lymph node or any other lymph node after surgery (isolated tumor cells [N0(i+)] are not allowed);

• No evidence of nodal or distant metastases (cN0M0) on pre and/or postoperative imaging examinations (performed following local/national guidelines, but must include an 18F-fluorodeoxyglucose positron emission tomography/computed tomography [18F-FDG-PET/CT, at least from skull base to upper legs] or computed tomography [CT] of neck/chest/abdomen/pelvis [CT only if 18F-FDG-PET/CT would not be available; 18F-FDG-PET/CT mandatory in the Netherlands]);

• sTIL score of ≥50% for patients ≥40 years at the time of TNBC diagnosis and ≥75% for patients <40 years at the time of TNBC diagnosis on an H&E FFPE tissue slide on the surgical specimen, according to International Immuno-Oncology Biomarker Working Group on Breast Cancer (formerly International TILs Working Group) guidelines, by local and central review

• Has undergone curative breast surgery (breast-conserving surgery or mastectomy and surgical axillary staging [including at least sentinel lymph node procedure]);

• Absence of recurrence between curative breast surgery and expression of patient preference;

• Eligible for radiotherapy (if indicated).

Exclusion Criteria:

• Prior disease history of invasive and/or non-invasive breast cancer, or ongoing treatment for invasive and/or non-invasive breast cancer;
• Multifocal, multicentric or bilateral breast cancer at the time of screening;
• Administration of neoadjuvant systemic therapy;
• Presence of lymphovascular invasion on the diagnostic biopsy and/or the surgical specimen;
• Other invasive malignancy within 5 years prior to inclusion, with the exception of ade-quately treated non-melanoma skin cancer, localized cervical cancer, localized and Gleason ≤6 prostate cancer;
• Uncontrolled severe illness or medical condition;
• Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed and discussed with the patient before the enrolment in the in the trial.

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

The Netherlands Cancer InstituteOTHER

Collaborators

Maarten van de Weijden FoundationUNKNOWN

AVL FoundationUNKNOWN

m.kok@nki.nl+3120512 ext. 9111

• OPTimizing Irradiation Through Molecular Assessment of Lymph Node (OPTIMAL)

  NCT02335957

  CompletedInterventionalNot ApplicableUpdated Apr 1, 2022
• Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC

  NCT05645380

  Active, not recruitingInterventionalPhase 2Updated Apr 28, 2026
• Optimal Combination of Adjuvant Radiotherapy and Immunotherapy for Breast Cancer

  NCT07046195

  Active, not recruitingObservationalUpdated Jul 1, 2025
• TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer

  NCT06931769

  RecruitingObservationalUpdated May 13, 2026
• Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

  NCT06078384

  RecruitingInterventionalPhase 2Updated Jul 24, 2026
• Stromal Tumor-Infiltrating Lymphocyte Levels Are Associated With Immune Checkpoint Proteins In Triple Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

  NCT06965361

  CompletedObservationalUpdated May 16, 2025